ArticleAmerican journal of translational research2019
Long non-coding RNA H19 regulates cell growth and metastasis via miR-138 in breast cancer.
Article in American journal of translational research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 59 citations in OpenAlex.
- Noncoding RNAs in Metabolic Reprogramming of Breast Cancer: Dietary Opportunities and Translational Implications.Experientia supplementum (2012) · 2026Review
- miRNA and Its Implications in the Treatment Resistance in Breast Cancer-Narrative Review of What Do We Know So Far.Non-coding RNA · 2025Review
- SOX4 promotes triple-negative breast cancer progression by promoting SRPX2 transcription to regulate AKR1C1.Journal of molecular histology · 2025Article
- Non-coding RNAs, a double-edged sword in breast cancer prognosis.Cancer cell international · 2025Review
- Oral squamous cell carcinoma pharmacological treatment; A long non-coding RNAs (long ncRNAs) story.International journal of molecular and cellular medicine · 2025Review
- LncRNA H19 Activates the RAS-MAPK Signaling Pathway via miR-140-5p/SOS1 Axis in Malignant Liver Tumors.Current medical science · 2024Article
- The crosstalk between non-coding RNAs and cell-cycle events: A new frontier in cancer therapy.Molecular therapy. Oncology · 2024Review
- Cuprotosis clusters predict prognosis and immunotherapy response in low-grade glioma.Apoptosis : an international journal on programmed cell death · 2024Article
- Harnessing the potential of long non-coding RNAs in breast cancer: from etiology to treatment resistance and clinical applications.Frontiers in oncology · 2024Review
- Non-Coding RNAs in Human Cancer and Other Diseases: Overview of the Diagnostic Potential.International journal of molecular sciences · 2023Review
- Long non-coding RNA H19: a potential biomarker and therapeutic target in human malignant tumors.Clinical and experimental medicine · 2023Review
- Linc-ROR Promotes EMT by Targeting miR-204-5p/SMAD4 in Endometriosis.Reproductive sciences (Thousand Oaks, Calif.) · 2023Article
- Regulatory miRNAs, circRNAs and lncRNAs in cell cycle progression of breast cancer.Functional & integrative genomics · 2023Review
- Is H19 RNA a Useful Marker of Acromegaly and Its Complications? A Preliminary Study.Biomedicines · 2023Article
- Metformin and long non-coding RNAs in breast cancer.Journal of translational medicine · 2023Review
- LncRNA H19: a novel player in the regulation of diabetic kidney disease.Frontiers in endocrinology · 2023Review
- Roles and Mechanisms of Long Non-Coding RNAs in Breast Cancer.International journal of molecular sciences · 2022Review
- Blood-derived lncRNAs as biomarkers for cancer diagnosis: the Good, the Bad and the Beauty.NPJ precision oncology · 2022Review
- Circular RNA circ_0000518 promotes breast cancer progression through the microRNA-1225-3p/SRY-box transcription factor 4 pathway.Bioengineered · 2022Article
- Coding roles of long non-coding RNAs in breast cancer: Emerging molecular diagnostic biomarkers and potential therapeutic targets with special reference to chemotherapy resistance.Frontiers in genetics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is one of the most common cancers among women. Long non-coding RNAs (lncRNAs) are involved in the initiation and development of breast cancer and lncRNA H19 is a potential oncogenic factor; however, the underlying mechanisms remain unknown. In the present study, the regulatory functions of H19 in breast cancer were investigated. We found that H19 was upregulated in breast cancer tissues and cells and associated with poor prognosis. MiR-138 was downregulated in breast cancer tissues and negatively correlated with the expression of H19 and SOX4. Furthermore, SOX4 was upregulated in breast cancer tissues and positively correlated with H19. Downregulated H19 suppressed the proliferation, invasion and migration of breast cancer cells, but promoted cell cycle arrest and apoptosis. Additionally, miR-138 was identified as a direct target of H19 and SOX4; overexpression of miR-138 inhibited the proliferation, invasion and migration of MDA-MB-231 and MCF-7 cells, but promoted apoptosis, which were abrogated by SOX4 overexpression. Downregulated miR-138 induced cell proliferation, invasion and migration, but inhibited apoptosis of MDA-MB-231 and MCF-7 cells, which were promoted by SOX4 overexpression. In addition, miR-138 overexpression reversed the effects of H19 in breast cancer cells; silencing of H19 inhibited tumor growth and downregulate EMT markers
Indexed as
Identifiers
31217890PMC6556666W2986508412What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.